Takeda Pharmaceutical (TAK) Competitors

Sanofi (NASDAQ:SNY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability, media sentiment and community ranking.

Which has higher earnings and valuation, SNY or TAK?

Sanofi has higher earnings, but lower revenue than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$44.29B	2.98	$6.02B	$2.80	18.69
Takeda Pharmaceutical	$4.58T	0.01	$994.06M	$0.40	37.58

Does the MarketBeat Community prefer SNY or TAK?

Takeda Pharmaceutical received 50 more outperform votes than Sanofi when rated by MarketBeat users. However, 60.71% of users gave Sanofi an outperform vote while only 57.06% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Sanofi	Outperform Votes 51 60.71%	Underperform Votes 33 39.29%
Takeda Pharmaceutical	Outperform Votes 101 57.06%	Underperform Votes 76 42.94%

Which has more risk & volatility, SNY or TAK?

Sanofi has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.

Is SNY or TAK more profitable?

Sanofi has a net margin of 12.77% compared to Takeda Pharmaceutical's net margin of 4.53%. Sanofi's return on equity of 25.61% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	12.77%	25.61%	14.72%
Takeda Pharmaceutical	4.53%	9.39%	4.53%

Is SNY or TAK a better dividend stock?

Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.1%. Takeda Pharmaceutical pays an annual dividend of $0.53 per share and has a dividend yield of 3.5%. Sanofi pays out 57.1% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 132.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Do institutionals & insiders have more ownership in SNY or TAK?

14.0% of Sanofi shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the media refer more to SNY or TAK?

In the previous week, Sanofi had 23 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 30 mentions for Sanofi and 7 mentions for Takeda Pharmaceutical. Sanofi's average media sentiment score of 1.15 beat Takeda Pharmaceutical's score of 0.84 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	18 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate SNY or TAK?

Sanofi presently has a consensus target price of $63.33, suggesting a potential upside of 21.05%. Given Sanofi's higher possible upside, equities analysts clearly believe Sanofi is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Sanofi beats Takeda Pharmaceutical on 16 of the 20 factors compared between the two stocks.